Related Experiment Video

Updated: Feb 21, 2026

Quantification of Colonic Stem Cell Mutations
07:53

Quantification of Colonic Stem Cell Mutations

Published on: September 25, 2015

7.1K

Prevalence of glucose-6-phosphate dehydrogenase deficiency in neonates in Egypt

Soheir Abo Elella, Mahaa Tawfik, Naglaa Barseem

  • 1Correspondence: Dr. Wafaa Moustafa Department of Pediatrics, Manoufia University Faculty of Medicine, Shebin El-Kom, Cairo 00020, Egypt T: + 2001145388818 wafaamoustafa60@yahoo.com ORCID: http://orcid.org/0000-0001-7317-6507.

Annals of Saudi Medicine
|October 9, 2017
PubMed

Insights

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic disorder, was studied in newborns. This research aimed to find the local prevalence of G6PD deficiency, which can cause jaundice and hemolytic anemia.

Area of Science:

  • Genetics
  • Pediatrics
  • Biochemistry

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked genetic disorder.
  • It is a significant cause of neonatal jaundice and can lead to hemolytic manifestations.
  • Understanding its prevalence is crucial for public health management.

Purpose of the Study:

  • To determine the local prevalence of Glucose-6-phosphate dehydrogenase (G6PD) deficiency in newborns.
  • To establish baseline data for screening and management strategies.
  • To assess the impact of G6PD deficiency in a specific geographic region.

Main Methods:

  • A cross-sectional study design was employed.
  • Newborns born in 2015 at a university hospital were prospectively screened.
  • Quantitative G6PD enzyme activity was measured using fluorometric analysis of dried blood spot samples.

Main Results:

  • The study successfully screened newborns for G6PD deficiency.
  • Quantitative enzyme activity measurements provided data on deficiency levels.
  • Prevalence rates were established based on the collected data.

Conclusions:

  • The local prevalence of G6PD deficiency in newborns was determined.
  • Findings provide essential data for targeted newborn screening programs.
  • This study contributes to the understanding of G6PD deficiency epidemiology.
Abstract

More Related Videos

Biochemical Measurement of Neonatal Hypoxia13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

14.4K
Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina07:04

Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina

Published on: March 14, 2025

802

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
937
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.7K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Other Glycolytic Pathways01:24

Other Glycolytic Pathways

The pentose phosphate pathway (PPP) operates in parallel with glycolysis, facilitating the metabolism of both pentoses and glucose. This pathway consists of two distinct phases: the oxidative and non-oxidative phases. While it does not directly generate ATP, the intermediates formed during the process can integrate into glycolysis, contributing to cellular energy metabolism when required.Oxidative Phase: NADPH ProductionThe oxidative phase of the pentose phosphate pathway is primarily...
1.0K